Table a3 Distributions used in the probabilistic sensitivity analysis
Parameter | Distribution | alpha | beta |
|---|---|---|---|
Patients with metastasis* | Beta | 135 | 268 |
Blue dye detection rate | Beta | 202 | 92 |
99mTc detection rate | Beta | 227 | 13 |
Blue dye + 99mTc detection rate | Beta | 1050 | 25 |
Negative predictive value of H&E + ultrastaging* | Beta | 253 | 6 |
Sensitivity of H&E | Beta | 80 | 55 |
Local recurrence | Beta | 34 | 242 |
Groin recurrence following IFL (no SLN biopsy) | Beta | 1 | 31 |
Groin Recurrence following positive SLN biopsy and IFL | Beta | 11 | 124 |
Death following a local recurrence | Beta | 5 | 29 |
Death following a groin recurrence | Beta | 9 | 2 |
RT following IFL in the comparison arm | Beta | 26 | 30 |
RT with IFL following a true positive histopathology result | Beta | 49 | 68 |
Short-term morbidity following IFL | Beta | 22.6 | 24.4 |
Short-term morbidity following SLN biopsy | Beta | 41.4 | 222.6 |
Long-term morbidity following IFL + RT | Beta | 23.7 | 25.3 |
Long-term morbidity following IFL without RT | Beta | 20.9 | 49.1 |
Long-term morbidity following SLN Biopsy | Beta | 6.1 | 257.9 |
Bed days following a primary excision/SLN biopsy | Gamma | 1.925 | 2.007 |
Bed days following a IFL | Gamma | 3.504 | 1.6103 |
